The Company develops cell therapy product candidates derived from pluripotent stem cells, primarily focusing on rare and orphan indications including geographic atrophy for age-related macular degeneration and acute spinal cord injury. Its core portfolio includes OpRegen, developed in collaboration with Roche/Genentech, and OPC1, supported by public stem cell research funding, both employing the Company's proprietary AlloSCOPE manufacturing platform. The Company generates revenue through strategic collaborations and milestone payments from pharmaceutical partners, while conducting all cGMP manufacturing operations through its subsidiary facility in Jerusalem, Israel, leveraging pluripotent stem cell technology to address unmet medical needs in underserved patient populations with limited existing treatment options.